Modified optimal fractionation for poor prognosis malignant gliomas: an elusive search.
The prognosis of malignant gliomas has not changed much over the last few decades despite refinements in neurosurgical techniques, high-precision radiotherapy, and newer chemotherapeutic agents. The median survival of poor prognosis malignant gliomas (older and/or poor performance status patients) still remains in the range of 6-9 months following maximal safe resection and postoperative conventionally fractionated adjuvant radiotherapy with or without chemotherapy. However, six weeks of daily radiotherapy does seem inappropriate in relation to the short expected survival time in this subset and there is an increasing emphasis on reducing the overall treatment time and the number of hospital visits by such patients. This can be achieved either by accelerated radiotherapy or by hypofractionated radiation, both of which are equivalent to conventional fractionation in terms of palliative effect and survival, as in discussed in this review. Despite enough evidence, such alteration of fractionation has not gained widespread acceptance by the oncologic fraternity. This review has been conducted to collate the evidence that could help shift the paradigm from conventional to modified fractionation in poor prognosis malignant glioma patients.
Gupta
Tejpal
T
CRC, ACTREC, Tata Memorial Centre, Kharghar, Navi Mumbai, India. tejpalgupta@rediffmail.com
Dinshaw
Ketayun
K
D016543:Central Nervous System Neoplasms / Q000401:mortality / Q000532:radiotherapy*; D002986:Clinical Trials as Topic; D019583:Dose Fractionation, Radiation; D005910:Glioma / Q000401:mortality / Q000532:radiotherapy*; D006801:Humans; D011379:Prognosis; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome